Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes
暂无分享,去创建一个
David Botstein | Ash A. Alizadeh | Maximilian Diehn | Ash A Alizadeh | Ronald Levy | Peter J Oefner | D. Botstein | P. Brown | R. Levy | I. Lossos | R. Warnke | P. Oefner | M. Diehn | Y. Thorstenson | Patrick O Brown | Izidore S Lossos | Roger Warnke | Yvonne Thorstenson | R. Levy
[1] A. Zetterberg,et al. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[2] L. Larsson,et al. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.
[3] J Cairns,et al. Cold Spring Harbor Symposia. , 1968, Science.
[4] G. Prendergast,et al. Mechanisms of apoptosis by c-Myc , 1999, Oncogene.
[5] T. Colby,et al. Histologic conversion in the non-Hodgkin's lymphomas. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Llano,et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] E. Lander,et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[8] P. Lorigan,et al. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma , 2001, British Journal of Cancer.
[9] M. Gerretsen,et al. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.
[10] F. Marincola,et al. High-fidelity mRNA amplification for gene profiling , 2000, Nature Biotechnology.
[11] D. Longo,et al. p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.
[12] K. Offit,et al. Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. , 1987, Blood.
[13] M. Raffeld,et al. Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences. , 1995, Current topics in microbiology and immunology.
[14] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[15] J. Woodgett,et al. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.
[16] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[17] M. Raffeld,et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain , 1995, Molecular and cellular biology.
[18] S. Horning,et al. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.
[19] R. Gascoyne,et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. , 1998, Blood.
[20] R. Warnke,et al. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. , 1996, Blood.
[21] U. Weidle,et al. The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.
[22] D. Weisenburger,et al. Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). , 1988, Journal of the National Cancer Institute.
[23] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] p53 mutations are associated with histologic transformation of follicular lymphoma , 1993 .
[25] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] E. Campo,et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.
[27] Ash A. Alizadeh,et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.
[28] M. Oken,et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.
[29] Elaine S. Jaffe,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[30] I. Lossos,et al. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. , 2000, Blood.
[31] D. Longo,et al. MYC rearrangements in histologically progressed follicular lymphomas. , 1992, Blood.
[32] Gouri Nanjangud,et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.